Literature DB >> 24033634

Cancer therapeutics revisited; novel drugs targeting cell signalling pathways, genome wide association studies and other trials and tribulations.

Lionel D Lewis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24033634      PMCID： PMC3769659          DOI： 10.1111/bcp.12216

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  16 in total

1.  Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.

Authors:  L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

2.  Herbal product-drug interactions mediated by induction.

Authors:  Rommel G Tirona; David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 3.  A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.

Authors:  Rashmi R Shah; Samantha A Roberts; Devron R Shah
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 4.  Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Feng Lin; Yuan-Jue Sun; Li-Na Tang; Zan Shen; Yang Yao
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 5.  Exposure to bisphosphonates and risk of colorectal cancer.

Authors:  Jingjing Ma; Sheng Gao; Xiaojian Ni; Fei Chen; Xiaofeng Liu; Hui Xie; Hong Yin; Cheng Lu
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

6.  Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.

Authors:  Stefanos Bonovas; Georgios Nikolopoulos; Pantelis Bagos
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 7.  The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.

Authors:  Ruth Thompson; Alan Eastman
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

8.  Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

Authors:  J G Coen van Hasselt; Anubha Gupta; Ziad Hussein; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

9.  Effects of St. John's wort on irinotecan metabolism.

Authors:  Ron H J Mathijssen; Jaap Verweij; Peter de Bruijn; Walter J Loos; Alex Sparreboom
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.